Pfizer Could Launch US Bevacizumab This Year Despite Patent Thicket
Pfizer has secured FDA approval for its Zirabev becacizumab biosimilar. But Genentech is citing 22 patents it says should bar the rival to its Avastin oncology brand.
Pfizer has secured FDA approval for its Zirabev becacizumab biosimilar. But Genentech is citing 22 patents it says should bar the rival to its Avastin oncology brand.